Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast
Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a...
Tag : Zydus Lifesciences
Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)
The Phase 2 clinical trial will assess the safety and efficacy of ZYIL1 in Amyotrophic...